Skip to main content
  • English
  • Español
Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
      • Share Performance
      • Shares and Capital Structure
      • Dividends
      • Share Issues
      • Takeover Bids
      • Shareholdings
    • Financial Information
      • Financial Results and Accounts
      • Public Periodic Information
      • Average supplier payment period
    • CNMV Filings
    • Analyst Coverage
    • Corporate Governance
      • General Shareholders Meeting
      • Board of Directors
      • Board Committees
      • Shareholder Agreements
      • Annual Corporate Governance Reports
      • Annual Director Remuneration Reports
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us

Breadcrumb

  1. Home
29 May 2019

ORYZON announces First Patient in the US in ETHERAL-US: a Phase IIa clinical trial with vafidemstat in Alzheimer’s Disease

20 May 2019

ORYZON Receives $1.5 million grant from Alzheimer’s Drug Discovery Foundation (ADDF)

13 May 2019

ORYZON Reports Financial Results and Corporate Update for the 1st Quarter, 2019

6 May 2019

Oryzon to present at upcoming international conferences

25 April 2019

ORYZON to present vafidemstat efficacy data at the 7th World Congress on ADHD in Lisbon

15 April 2019

ORYZON to present further REIMAGINE efficacy data with vafidemstat at the 7th World Congress on ADHD in Lisbon

8 April 2019

ORYZON to present first in human efficacy data with Vafidemstat at the 27th European Congress of Psychiatry in Warsaw

5 April 2019

Oryzon to present at upcoming international conferences

25 March 2019

Oryzon to present at upcoming international conferences

20 March 2019

Oryzon to present latest advances of Vafidemstat at Oppenheimer’s 29th Annual Healthcare Conference

Pagination

  • First page « First
  • Previous page ‹ Previous
  • Page 36
  • Page 37
  • Page 38
  • Page 39
  • Current page 40
  • Page 41
  • Page 42
  • Page 43
  • Page 44
  • Next page Next ›
  • Last page Last »
Subscribe to
Logo Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
    • Financial Information
    • CNMV Filings
    • Analyst Coverage
    • Corporate Governance
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us
  • © Oryzon Genomics, S.A. - All Rights Reserved

    • Legal
    • Privacy Policy
    • Cookie Policy
    • Ethics Channel